January 9, 2018 12:49 PM EST

Global Blood Therapeutics' sickle cell disease drug gets breakthrough therapy status; Boehringer Ingelheim will manufacture BeiGene's PD-1 inhibitor in Shanghai

Amber Tong

→ Global Blood Therapeutics just got breakthrough therapy designation from the FDA for its all important sickle cell disease drug, voxelotor (GBT440). The decision …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Global Blood Therapeutics' sickle cell disease drug gets breakthrough therapy status; Boehringer Ingelheim will manufacture BeiGene's PD-1 inhibitor in Shanghai

Amber Tong

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Trump blog: Top HHS spokesperson resigns within weeks of being sworn in

ICER finds GSK inhalers offer advantages over generic competitors

Pliant calls it quits on Phase 2b idiopathic pulmonary fibrosis study

Biohaven’s ion channel drug fails pivotal bipolar mania study

Novo Nordisk signs $354M partnership with AI-guided biotech for ‘risky’ new metabolic mechanisms

The perfect storm: Why everything is in place for 2025 to be the year of GxP AI

Glob­al Blood Ther­a­peu­tic­s' sick­le cell dis­ease drug gets break­through ther­a­py sta­tus; Boehringer In­gel­heim will man­u­fac­ture BeiGene's PD-1 in­hibitor in Shang­hai

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Global Blood Therapeutics' sickle cell disease drug gets breakthrough therapy status; Boehringer Ingelheim will manufacture BeiGene's PD-1 inhibitor in Shanghai